Undifferentiated connective tissue disease medical therapy: Difference between revisions

	Undifferentiated connective tissue disease Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Undifferentiated connective tissue disease from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
CT
MRI
Other imaging findings
Other diagnostic studies
Treatment
Medical Therapy
Surgery
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Undifferentiated connective tissue disease medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Undifferentiated connective tissue disease medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Undifferentiated connective tissue disease medical therapy
CDC on Undifferentiated connective tissue disease medical therapy
Undifferentiated connective tissue disease medical therapy in the news
Blogs on Undifferentiated connective tissue disease medical therapy
Directions to Hospitals Treating Undifferentiated connective tissue disease
Risk calculators and risk factors for Undifferentiated connective tissue disease medical therapy

VisualWikitext

Latest revision as of 18:30, 30 May 2018

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2]

Overview

The pharmacologic medical therapy is recommended based on the rheumatic disease pattern manifested by the patient such as methotrexate in those exhibiting arthritis and dermatitis. Supportive therapy includes; avoiding cold exposure in those experiencing Raynaud's phenomenon, avoiding sun in photosensitivity, non-steroidal anti-inflammatory drugs for pain control, sunscreen used for photosensitivity, and emollients for dry skin and rash.

Medical Therapy

Routine measures

Avoiding cold exposure in those experiencing Raynaud's phenomenon
Avoiding sun in photosensitivity

Supportive therapy

Non-steroidal anti-inflammatory drugs for pain control
Sunscreen used for photosensitivity
Emollients for dry skin, rash

Arthritis and dermatitis

Oral regimen
- Preferred regimen (1): Methotrexate 7.5 mg PO q24h for 6 months (not used for CNS symptoms or serositis)^[1]
  - Dose can be gradually increased to 13.6 mg after 6 months

References

↑ Wise CM, Vuyyuru S, Roberts WN (June 1996). "Methotrexate in nonrenal lupus and undifferentiated connective tissue disease--a review of 36 patients". J. Rheumatol. 23 (6): 1005–10. PMID 8782131.

Template:WH Template:WS

[pmid8782131-1] Wise CM, Vuyyuru S, Roberts WN (June 1996). "Methotrexate in nonrenal lupus and undifferentiated connective tissue disease--a review of 36 patients". J. Rheumatol. 23 (6): 1005–10. PMID 8782131.

[1]

@@ Line 1: / Line 1: @@
 __NOTOC__
 {{Undifferentiated connective tissue disease}}
-{{CMG}} {{AE}}
+{{CMG}} {{AE}}{{ADS}}
 ==Overview==
-The pharmacologic medical therapy is recommended based on the rheumatic disease pattern manifested by the patient such as [[methotrexate]] in those exhibiting [[arthritis]] and [[dermatitis]].
+The pharmacologic medical therapy is recommended based on the rheumatic disease pattern manifested by the patient such as [[methotrexate]] in those exhibiting [[arthritis]] and [[dermatitis]]. Supportive therapy includes; avoiding cold exposure in those experiencing [[Raynaud's phenomenon]], avoiding sun in [[photosensitivity]], [[Non-steroidal anti-inflammatory drug|non-steroidal anti-inflammatory drugs]] for pain control, [[sunscreen]] used for [[photosensitivity]], and [[emollients]] for dry skin and rash.
 ==Medical Therapy==
-*Pharmacologic medical therapy is recommended based on the rheumatic disease pattern manifested by the patient:
-=== Arthritis and dermatitis ===
-* Oral regimen
-** Preferred regimen (1): [[Methotrexate]] 7.5 mg PO q24h for 6 months '''(not used for CNS symptoms or serositis)'''<ref name="pmid8782131">{{cite journal |vauthors=Wise CM, Vuyyuru S, Roberts WN |title=Methotrexate in nonrenal lupus and undifferentiated connective tissue disease--a review of 36 patients |journal=J. Rheumatol. |volume=23 |issue=6 |pages=1005–10 |date=June 1996 |pmid=8782131 |doi= |url=}}</ref>
+=== Routine measures ===
-*** Dose is gradually increased to 13.6 mg after 6 months
+* Avoiding cold exposure in those experiencing [[Raynaud's phenomenon]]
-***
+* Avoiding sun in [[photosensitivity]]
+=== Supportive therapy ===
+* [[Non-steroidal anti-inflammatory drug|Non-steroidal anti-inflammatory drugs]] for pain control
+* [[Sunscreen]] used for [[photosensitivity]]
+* [[Emollients]] for dry skin, rash
-**** Parenteral regimen
+=== Arthritis and dermatitis ===
-***** Preferred regimen (1): [[drug name]] 2 g IV q24h for 14 (14–21) days
+*Oral regimen
-***** Alternative regimen (1): [[drug name]] 2 g IV q8h for 14 (14–21) days
+**Preferred regimen (1): [[Methotrexate]] 7.5 mg PO q24h for 6 months '''(not used for CNS symptoms or serositis)'''<ref name="pmid8782131">{{cite journal |vauthors=Wise CM, Vuyyuru S, Roberts WN |title=Methotrexate in nonrenal lupus and undifferentiated connective tissue disease--a review of 36 patients |journal=J. Rheumatol. |volume=23 |issue=6 |pages=1005–10 |date=June 1996 |pmid=8782131 |doi= |url=}}</ref>
-***** Alternative regimen (2): [[drug name]] 18–24 MU/day IV q4h for 14 (14–21) days
+*** Dose can be gradually increased to 13.6 mg after 6 months
-***** Preferred regimen (1): [[drug name]] 500 mg PO q8h for 14 (14–21) days
-***** Preferred regimen (2): [[drug name]] 100 mg PO q12h for 14 (14–21) days
-***** Preferred regimen (3): [[drug name]] 500 mg PO q12h for 14 (14–21) days
-***** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days
-***** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
-***** Alternative regimen (3):[[drug name]] 500 mg PO q6h for 14–21 days
-*** 2.1.2 '''Pediatric'''
-**** Parenteral regimen
-***** Preferred regimen (1): [[drug name]] 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
-***** Alternative regimen (1): [[drug name]] 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
-***** Alternative regimen (2):  [[drug name]] 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day) '<nowiki/>'''''(Contraindications/specific instructions)''''''
-**** Oral regimen
-***** Preferred regimen (1):  [[drug name]] 50 mg/kg/day PO q8h for 14 (14–21) days  (maximum, 500 mg per dose)
-***** Preferred regimen (2): [[drug name]] '''(for children aged ≥ 8 years)''' 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
-***** Preferred regimen (3): [[drug name]] 30 mg/kg/day PO q12h for 14 (14–21) days  (maximum, 500 mg per dose)
-***** Alternative regimen (1):  [[drug name]] 10 mg/kg PO q6h 7–10 days  (maximum, 500 mg per day)
-***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h for 14–21 days  (maximum, 500 mg per dose)
-***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h for 14–21 days  (maximum,500 mg per dose)
 ==References==